Loading data for DYN — first visit, this takes a few seconds.

Alert

Dyne Therapeutics Inc. (DYN)

NasdaqGS: DYN · Real-Time Price · USD

26.10

+0.12 (0.46%)

At close: Aug 21, 2026, 3:59 PM

26.10

+0.00%

After-hours: 7:30 PM

The price, the headline numbers and the latest news, in one place.

0.46% (1D)

Bid	19.32
Market Cap	4.87B
Revenue (ttm)	n/a
Net Income (ttm)	-519.4M
	1.08
	-3.26
	n/a
	-7.81
P/B (ttm)	6.16
P/S (ttm)	n/a
Earnings Date	Nov 5, 2026

Ask	33.61
Volume	1,162,265
Avg. Volume (20D)	2,223,148
Open	26.21
Previous Close	25.98
Day's Range	26.06 - 26.87
52-Week Range	11.92 - 27.30
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About DYN

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases usin...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Sep 17, 2020

Employees 289

Stock Exchange NasdaqGS

Ticker Symbol DYN

Website https://www.dyne-tx.com

Full Company Profile

Financial Performance

In 2025, Dyne Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -446.21M, an increase of 40.58%.

Financial Statements

Earnings Surprise

Dyne Therapeutics has released their quarterly earnings on Jul 29, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.
EPS of -1.08 misses estimates by -0.33, with -11.34% YoY decline.

Next Earnings Release

Dyne Therapeutics Inc. is scheduled to release its earnings on Nov 5, 2026, during market hours.
Analysts project revenue of ... Upgrade

News

1 month ago · Simply Wall St.

Dyne Therapeutics (DYN) Prices Upsized Share Offering, Is The Valuation Still Compelling?

Dyne Therapeutics (DYN) is back in focus after pricing an upsized follow on equity offering of 18,300,000 common shares at $20.50 each, raising about $375 million in gross proceeds. See our latest ana...

1 month ago · Zacks

SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat?

Sarepta falls nearly 10% in a week after Dyne Therapeutics wins FDA priority review for a rival DMD therapy that could challenge Exondys 51 if approved.

1 month ago · MT Newswires

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Ahead of Major Tech Earnings

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) retreated 0.4%, and the actively

1 month ago · InvestorsHub

Dyne Therapeutics shares slide after pricing $375 million public offering (NASDAQ:DYN)

Discounted share sale weighs on stockDyne Therapeutics, Inc. (NASDAQ:DYN) shares fell 9% on Wednesday after the biotechnology company priced a public offering of common stock expected to raise approxi...

1 month ago · Stocktwits

Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock

Dyne Therapeutics announced plans to raise $300 million through a public stock offering on Tuesday.

Page 1 of 2

Dyne Therapeutics Inc. (DYN)